Hepatic Disease Clinical Trial
— PARAFOIOfficial title:
Paracetamol Metabolism Research in Postoperative Hepatic Surgery
The main objective of this study was to evaluate the 5-day kinetics of plasma paracetamol
levels in postoperative major hepatic surgery (resection greater than or equal to three
hepatic segments) compared with less extensive liver resection and hepatic re-intervention.
The clearance of indocyanine green is a marker of hepatic perfusion but also of the proper
hepatocyte functioning, if hemodynamic conditions are stable.
Some patients may be operated on up to four or five times in the liver. Moreover, these
patients probably present an increased risk of postoperative hepatocellular insufficiency due
to a quantitative and qualitative decrease in their hepatic parenchyma. It is therefore
interesting to evaluate the use of paracetamol in this situation.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | January 2020 |
Est. primary completion date | January 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients requiring surgery for hepatic resection by initiation under chest or laparoscopic without hepatocellular insufficiency, - ASA score 1 to 3 (American Society of Anesthesiologists score ranging from 1 to 5 evaluating the preoperative health status of a patient), - Verification of the understanding of the protocol, Exclusion Criteria: - Patients classified ASA 4 or 5, - Allergy or intolerance to indocyanine green - Allergy or intolerance to paracetamol, - Taking of paracetamol the week before the intervention, - Patient less than 60 Kgs (because decrease of doses of paracetamol), - Emergency surgery, palliative surgery and surgical recovery, - Psychic disorder, - Contra-indication to a treatment used during the study, - incapable major, - Intellectual incapacity preventing proper understanding of the protocol, - Pregnant or nursing woman, |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Huriez, CHRU | Lille |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Lille |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dosing and kinetics of paracetamolemia | this determination of the plasma paracetamol dosage on D0 (H6: 6 hours after the end of the procedure) and D1 D2 D3 D4 D5 (samples taken at 6 am each day just before the injection of paracetamol whose administration hours will be 6h 12h 18h and midnight) | during the 5 post-operative days | |
Secondary | Dosage of urinary metabolites of paracetamol (paracetamol sulphate, paracetamol glucuronide) | At Day 1, day 3, day 5 post operative | ||
Secondary | Dosage of N-acetyl-cysteinyl paracetamol ( NAPQI) | At Day 1, day 3, day 5 post operative | ||
Secondary | Percentage of patients with paracetamolemia greater than 60 mg / mL | 60mj/ml = paracetamol toxicity threshold according to Prescott diagram to 6 hours | during the 5 post-operative days | |
Secondary | Plasma Disappearance Rate of indocyanine green (TDP-ICG) by LiMon® | At Day 1, day 3, day 5 post operative | ||
Secondary | Rate of postoperative hepatocellular insufficiency | The postoperative hepatocellular insufficiency according to the 50/50 criteria (TP <50% and bilirubinemia> 50 µmol / L on the 5th day) according to the type of hepatic resection (with or without clamping, continuous or discontinuous, duration intervention). | at day 5 | |
Secondary | Occurrence of complications related to hepatic failure | the complications related to hepatic failure not falling within the "50/50" criteria: jaundice, hepatic encephalopathy, coagulation disorders, ascites, cytolysis, cholestasis. Other medical and surgical. Duration of hospitalization in perioperative intensive care and duration of total hospitalization. Mortality at 30 days. |
at day 5 | |
Secondary | Duration of hospitalization in perioperative intensive care | at 30 days | ||
Secondary | Duration of total hospitalization. | at 30 days | ||
Secondary | Mortality | at 30 days | ||
Secondary | Composite characteristics of surgery. | Characteristics of surgery: duration of intervention, numbers, duration and types of vascular clamping, detailed description of the type of liver resection performed, quantification of bleeding. | at 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05593211 -
Assess Safety and Performance of the Kronos Electrocautery Device for Electrocautery Procedures Following Coaxial Biopsy Procedures
|
N/A | |
Terminated |
NCT02104154 -
Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care Setting
|
N/A | |
Not yet recruiting |
NCT06153394 -
Prolonged Hypercoagulability Following Major Liver Resection for Malignancy
|
Phase 3 | |
Completed |
NCT03652636 -
Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions
|
Phase 4 | |
Recruiting |
NCT05822635 -
SpyGlass Surgical Study
|
||
Not yet recruiting |
NCT05616442 -
Ketotifen in Non-Alcoholic Fatty Liver Disease Patients
|
Phase 4 | |
Completed |
NCT03767517 -
A Culturally-Based Palliative Care Tele-consult Program for Rural Southern Elders
|
N/A |